Independent generation of Aβ42 and Aβ38 peptide species by γ-secretase

被引:70
作者
Czirr, Eva [1 ]
Cottrell, Barbara A. [2 ]
Leuchtenberger, Stefanie [1 ]
Kukar, Thomas [6 ]
Ladd, Thomas B. [6 ]
Esselmann, Hermann [7 ]
Paul, Sabine [7 ]
Schubenel, Robert [5 ]
Torpey, Justin W. [3 ]
Pietrzik, Claus U. [4 ]
Golde, Todd E. [6 ]
Wiltfang, Jens [7 ]
Baumann, Karlheinz [5 ]
Koo, Edward H. [2 ]
Weggen, Sascha [1 ]
机构
[1] Univ Dusseldorf, Dept Neuropathol, Mol Neuropathol Grp, D-40225 Dusseldorf, Germany
[2] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Dept Biomol Mass Spectrometry Facil, La Jolla, CA 92093 USA
[4] Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, Mol Neurodegenerat Grp, D-55128 Mainz, Germany
[5] F Hoffmann La Roche & Co Ltd, Preclin Res CNS, Div Pharmaceut, CH-4070 Basel, Switzerland
[6] Mayo Clin, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA
[7] Univ Duisburg Essen, Rhine State Hosp, Dept Psychiat & Psychotherapy, D-45147 Essen, Germany
关键词
D O I
10.1074/jbc.M802912200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proteolytic processing of the amyloid precursor protein by beta- and gamma-secretase generates the amyloid-beta (A beta) peptides, which are principal drug targets in Alzheimer disease therapeutics. gamma-Secretase has imprecise cleavage specificity and generates the most abundant A beta 40 and A beta 42 species together with longer and shorter peptides such as A beta 38. Several mechanisms could explain the production of multiple A beta peptides by gamma-secretase, including sequential processing of longer into shorter A beta peptides. A novel class of gamma-secretase modulators (GSMs) that includes some non-steroidal anti-inflammatory drugs has been shown to selectively lower A beta 42 levels with out a change in A beta 40 levels. A signature of GSMs is the concomitant increase in shorter A beta peptides, such as A beta 38, leading to the suggestion that generation of A beta 42 and A beta 38 peptide species by gamma-secretase is coordinately regulated. However, no evidence for or against such a precursor-product relationship has been provided. We have previously shown that stable overexpression of aggressive presenilin-1 (PS1) mutations associated with early-onset familial Alzheimer disease attenuated the cellular response to GSMs, resulting in greatly diminished A beta 42 reductions as compared with wild type PS1. We have now used this model system to investigate whether A beta 38 production would be similarly affected indicating coupled generation of A beta 42 and A beta 38 peptides. Surprisingly, treatment with the GSM sulindac sulfide increased A beta 38 production to similar levels in four different PS1 mutant cell lines as compared with wild type PS1 cells. This was confirmed with the structurally divergent GSMs ibuprofen and indomethacin. Mass spectrometry analysis and high resolution urea gel electrophoresis further demonstrated that sulindac sulfide did not induce detectable compensatory changes in levels of other A beta peptide species. These data provide evidence that A beta 42 and A beta 38 species can be independently generated by gamma-secretase and argue against a precursor-product relationship between these peptides.
引用
收藏
页码:17049 / 17054
页数:6
相关论文
共 29 条
[1]   Selected non-steroidal anti-inflammatory drugs and their derivatives target γ-secretase at a novel site -: Evidence for an allosteric mechanism [J].
Beher, D ;
Clarke, EE ;
Wrigley, JDJ ;
Martin, ACL ;
Nadin, A ;
Churcher, I ;
Shearman, MS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (42) :43419-43426
[2]   Presenilin clinical mutations can affect γ-secretase activity by different mechanisms [J].
Bentahir, M ;
Nyabi, O ;
Verhamme, J ;
Tolia, A ;
Horré, K ;
Wiltfang, J ;
Esselmann, H ;
De Strooper, B .
JOURNAL OF NEUROCHEMISTRY, 2006, 96 (03) :732-742
[3]   Insensitivity to Aβ42-lowering nonsteroidal anti-inflammatory drugs and γ-secretase inhibitors is common among aggressive presenilin-1 mutations [J].
Czirr, Eva ;
Leuchtenberger, Stefanie ;
Dorner-Ciossek, Cornelia ;
Schneider, Anna ;
Jucker, Mathias ;
Koo, Edward H. ;
Pietrzik, Claus U. ;
Baumann, Karlheinz ;
Weggen, Sascha .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (34) :24504-24513
[4]   Loss-of-function presenilin mutations in Alzheimer disease - Talking Point on the role of presenilin mutations in Alzheimer disease [J].
De Strooper, Bart .
EMBO REPORTS, 2007, 8 (02) :141-146
[5]   NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo [J].
Eriksen, JL ;
Sagi, SA ;
Smith, TE ;
Weggen, S ;
Das, P ;
McLendon, DC ;
Ozols, VV ;
Jessing, KW ;
Zavitz, KH ;
Koo, EH ;
Golde, TE .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (03) :440-449
[6]   Purification and characterization of the human γ-secretase complex [J].
Fraering, PC ;
Ye, WJ ;
Strub, JM ;
Dolios, G ;
LaVoie, MJ ;
Ostaszewski, BL ;
van Dorsselaer, A ;
Wang, R ;
Selkoe, DJ ;
Wolfe, MS .
BIOCHEMISTRY, 2004, 43 (30) :9774-9789
[7]   Disease modifying therapy for AD? [J].
Golde, Todd E. .
JOURNAL OF NEUROCHEMISTRY, 2006, 99 (03) :689-707
[8]   1-(3′,4′-dichloro-2-fluoro[1,1′-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel γ-secretase modulator, reduces brain β-amyloid pathology in a Transgenic mouse model of Alzheimer's disease without causing peripheral toxicity [J].
Imbimbo, Bruno P. ;
Del Giudice, Elda ;
Colavito, Davide ;
D'Arrigo, Antonello ;
Carbonare, Maurizio Dalle ;
Villetti, Gino ;
Facchinetti, Fabrizio ;
Volta, Roberta ;
Pietrini, Vladimiro ;
Baroc, Maria F. ;
Serneels, Lutgarde ;
De Strooper, Bart ;
Leon, Alberta .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 323 (03) :822-830
[9]   Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Aβ42 production [J].
Kukar, T ;
Murphy, MP ;
Eriksen, JL ;
Sagi, SA ;
Weggen, S ;
Smith, TE ;
Ladd, T ;
Khan, MA ;
Kache, R ;
Beard, J ;
Dodson, M ;
Merit, S ;
Ozols, VV ;
Anastasiadis, PZ ;
Das, P ;
Fauq, A ;
Koo, EH ;
Golde, TE .
NATURE MEDICINE, 2005, 11 (05) :545-550
[10]   Selective modulation of Aβ42 production in Alzheimer's disease:: Non-steroidal anti-inflammatory drugs and beyond [J].
Leuchtenberger, Stefanie ;
Beher, Dirk ;
Weggen, Sascha .
CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (33) :4337-4355